## Amendments to and Listing of the Claims:

Please cancel claim 19, without prejudice, amend claims 5 and 7-10, without prejudice, and insert new claims 21-25, as set forth in the following listing of the claims:

1. (Previously Presented) A method of treating a human subject for exposure to ionizing radiation, said method comprising administering to the subject following the subject's exposure to the ionizing radiation an effective amount of a compound of formula I:

$$R_1S$$
 (alkyl)<sub>m</sub> (alkyl)<sub>n</sub>  $R_2$   $R_3$  .

wherein:

R<sub>1</sub> is hydrogen, lower alkyl, a sulfur-containing amino acid or

$$-s^{(alkyl)_m}$$
  $R_4$  ;

R<sub>2</sub> and R<sub>4</sub> are each individually SO<sub>3</sub><sup>-</sup>M<sup>+</sup>, PO<sub>3</sub><sup>2-</sup>M<sub>2</sub><sup>2+</sup>, or PO<sub>2</sub>S<sup>2-</sup>M<sub>2</sub><sup>2+</sup>;

 $R_3$  and  $R_5$  are each individually hydrogen, hydroxy or sulfhydryl, where if  $R_1$  is hydrogen,  $R_3$  is not sulfhydryl;

m and n are individually 0, 1, 2, 3 or 4, with the proviso that if m or n is 0, then  $R_3$  is hydrogen; and

M is hydrogen or an alkali metal ion; or a pharmaceutically acceptable salt thereof.

- 2. (Previously Presented) The method of Claim 1 wherein the formula I compound is 2,2'-dithiobis ethane sulfonic acid, or a disodium salt thereof, and the effective amount administered is from 0.1 mg/kg of body weight to 1,000 mg/kg of body weight of the subject.
- 3. (Original) The method of Claim 1 wherein the compound is administered orally.
- 4. (Original) The method of Claim 1 wherein the compound is administered parenterally.

2

5. (Currently Amended) A method of prophylactically treating a human subject about to undergo exposure to ionizing radiation, said method comprising administering intravenously or orally to the subject prior to being exposed to the ionizing radiation, an amount of a compound of formula I, other than mesna, in an amount and at a time effective to prophylactically protect the subject from adverse effects of the ionizing radiation:

(I)
$$R_{1}S \xrightarrow{(alkyl)_{m}} R_{2}$$

$$R_{3}$$

$$R_{3}$$

wherein:

R<sub>1</sub> is hydrogen, lower alkyl, a sulfur-containing amino acid or

$$-s^{(alkyl)_m}$$
  $R_4$ 

R<sub>2</sub> and R<sub>4</sub> are each individually SO<sub>3</sub>-M<sup>+</sup>, PO<sub>3</sub><sup>2</sup>-M<sub>2</sub><sup>2+</sup>, or PO<sub>2</sub>S<sup>2</sup>-M<sub>2</sub><sup>2+</sup>;

 $R_3$  and  $R_5$  are each individually hydrogen, hydroxy or sulfhydryl, where if  $R_1$  is hydrogen,  $R_3$  is not sulfhydryl;

m and n are individually 0, 1, 2, 3 or 4, with the proviso that if m or n is 0, then  $R_3$  is hydrogen; and

M is hydrogen or an alkali metal ion; or a pharmaceutically acceptable salt thereof.

- 6. (Previously Presented) The method of Claim 5 wherein the effective amount of the formula I compound to be administered is 500 mg/m<sup>2</sup> to 40g/m<sup>2</sup> of body surface area of the subject.
- 7. (Currently Amended) A method of prophylactically treating a human subject about to undergo exposure to ionizing radiation, the method comprising administering intravenously or orally to the subject 15 minutes to 1 hour prior to being exposed to the ionizing radiation, an amount of a compound of formula I effective to prophylactically protect the subject from adverse effects of the ionizing radiation:

3

$$\begin{array}{c} (\underline{I}) \\ R_1 S \xrightarrow{(alkyl)_m} (alkyl)_m R_2 \\ R_3 \end{array}$$

wherein:

R, is hydrogen, lower alkyl, a sulfur-containing amino acid or

$$-S$$
 (alkyl)m  $R_4$  ;

 $R_2$  and  $R_4$  are each individually  $SO_3^-M^+$ ,  $PO_3^{2-}M_2^{2+}$ , or  $PO_2S^{2-}M_2^{2+}$ ;

 $R_3$  and  $R_5$  are each individually hydrogen, hydroxy or sulfhydryl, where if  $R_1$  is hydrogen,  $R_3$  is not sulfhydryl;

m and n are individually 0, 1, 2, 3 or 4, with the proviso that if m or n is 0, then R<sub>3</sub> is hydrogen; and

M is hydrogen or an alkali metal ion; or

<u>a pharmaceutically acceptable salt thereof</u> wherein the formula I compound is administered to the subject at 15 minutes to 1 hour prior to the radiation exposure.

- 8. (Currently Amended) The method of Claim 5–7 wherein administration is by intravenous infusion.
- 9. (Currently Amended) The method of Claim 5-7 wherein administration is oral.
- 10. (Currently Amended) The method of Claim 5 A method of prophylactically treating a human subject about to undergo exposure to ionizing radiation, the method comprising administering intravenously or orally to the subject 15 minutes to 1 hour prior to being exposed to the ionizing radiation, an amount of a compound of formula I effective to prophylactically protect the subject from adverse effects of the ionizing radiation:

$$\begin{array}{c} (\underline{I}) \\ R_1 S \\ \hline \\ R_3 \end{array}$$

## wherein:

ř.

R<sub>1</sub> is hydrogen, lower alkyl, a sulfur-containing amino acid or

$$-S^{(alkyl)m} \xrightarrow{R_4} R_5$$

R<sub>2</sub> and R<sub>4</sub> are each individually  $SO_3^-M^+$ ,  $PO_3^{2-}M_2^{2+}$ , or  $PO_2S^2-M_2^{2+}$ ;

 $R_3$  and  $R_5$  are each individually hydrogen, hydroxy or sulfhydryl, where if  $R_1$  is hydrogen,  $R_3$  is not sulfhydryl;

m and n are individually 0, 1, 2, 3 or 4, with the proviso that if m or n is 0, then R<sub>3</sub> is hydrogen; and

M is hydrogen or an alkali metal ion; or

<u>a pharmaceutically acceptable salt thereof, and</u> wherein an additional effective dose of <u>the formula I compound is administered about 2 hours after conclusion of the radiation exposure.</u>

- 11. (Original) The method of Claim 10 wherein additional effective doses are administered to the patient about every 4 hours after the first-mentioned additional effective dose.
- 12. (Original) The method of Claim 10 wherein the additional effective dose is administered orally.
- 13. (Original) The method of Claim 10 wherein the additional effective dose is administered by intravenous infusion.

acid or

15. (Original) The method of Claim 5 wherein R<sub>1</sub> is lower alkyl, a sulfur-containing amino

$$-S \xrightarrow{\text{(alkyl)}_{m}} R_{4}$$
 acid or

- 16. (Previously Presented) The method of Claim 15 wherein the formula I compound to be administered is 2,2'-dithiobis ethane sulfonic acid, or a disodium salt thereof.
- 17. (Previously Presented) A method of protecting a human subject against ionizing radiation, the method comprising administering to the subject an amount effective to protect the subject from adverse effects of the ionizing radiation of a compound of formula I, other than mesna:

(I)
$$R_{1}S \xrightarrow{(alkyl)_{m}} R_{2}$$

$$R_{3} :$$

wherein:

R<sub>1</sub> is hydrogen, lower alkyl, a sulfur-containing amino acid or

$$-s^{(alkyl)_m}$$
  $R_4$ 

 $R_2$  and  $R_4$  are each individually  $SO_3^-M^+$ ,  $PO_3^{2-}M_2^{2+}$ , or  $PO_2S^2^-M_2^{2+}$ ;

 $R_3$  and  $R_5$  are each individually hydrogen, hydroxy or sulfhydryl, where if  $R_1$  is hydrogen,  $R_3$  is not sulfhydryl;

m and n are individually 0, 1, 2, 3 or 4, with the proviso that if m or n is 0, then  $R_3$  is hydrogen; and

M is hydrogen or an alkali metal ion; or a pharmaceutically acceptable salt thereof.

18. (Previously Presented) The method of Claim 17, wherein the compound is 2,2'-dithiobis ethane sulfonic acid, or a disodium salt thereof.

Application No. 10/002,526 Response to Office Action of November 3, 2005

- 19. (Canceled)
- 20. (Previously Presented) The method of claim 2 wherein the effective amount administered is from 20 mg/kg of body weight to 1,000 mg/kg of body weight of the subject.
- 21. (New) The method of Claim 5 wherein administration is by intravenous infusion.
- 22. (New) The method of Claim 5 wherein administration is oral.
- 23. (New) The method of Claim 17 wherein administration is by intravenous infusion.
- 24. (New) The method of Claim 17 wherein administration is oral.
- 25. (New) The method of Claim 17 wherein  $R_1$  is lower alkyl, a sulfur-containing amino

acid, or